iAMP COVID-19 Detection Kit
Qualitative nucleic acid detection of SARS-CoV-2 (COVID-19) on naso- or oropharyngeal swabs without pre-treatment.
Fast. Simple. Accurate.
Special Features:
-
Method:
-
Isothermal amplification with real time fluorescence detection
-
-
Simplicity:
-
Sample does not require pre-heating, RNA extraction nor purification
-
Limited hands-on time
-
-
Fast:
-
Sample-to-result between 75 to 90 minutes only
-
-
Accurate:
-
Methodology based on nucleic acid detection
-
-
Flexible:
-
Flexible sample numbers per run with no waste of reagents
-
-
Save:
-
Immediate virus inactivation by sample buffer
-
Product number 80767
Product number 80762
Click here to navigate
- Details
- Conditions of sale
- Documentation
- Insights
- Related products
-
Details
Technical Specifications:
- Sample types:
- Direct naso- or oropharyngeal dry swabs collected with Atila Sample Collection Device (iAMP-COVID19-SCD*)
- Alternatively, synthetic fiber swabs with plastic shafts and 1.5 mL collection tubes can be used
- Target regions:
- N and ORF-1ab from SARS-CoV-2
- N and ORF-1ab from SARS-CoV-2
- Reaction volume:
- 25 µL
- 25 µL
- Reaction time:
- Approximately 50 minutes
- Approximately 50 minutes
- Equipment:
- Atila PowerGene 9600 Plus Real-Time PCR system with 2 fluorescence channels FAM and HEX
- Or any other RT-PCR system with 2 fluorescence channels (FAM and HEX or similar wavelength channels) like Bio-Rad CFX96, Roche LightCycler 480 or Applied Biosystems 7500
* The iAMP COVID-19 Sample Collection Device is for Research Use Only; not for use in diagnostic procedures. Not yet available as CE marked product. - Sample types:
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all product documentation right away.
Other documents
FileISO13485_Atila_UQ-13951.pdf (pdf, 483.46 kb)FileDoc iAMP COVID-19 NDEGCE-TCF-001_a_0.pdf (pdf, 178.53 kb)Extra informationiAMP COVID-19 EC Declaration of ConformityGet access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Jan 6, 2022[Jan 2022 Update] This scientific literature overview demonstrates the excellent performance of the fully automated nucleocapsid protein antigen assay Lumipulse® G SARS-CoV-2 Ag
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
...
Oct 15, 2020Webinar: Lumipulse® G KL-6, the biomarker for routinely assessment of epithelial alveolar damage in pulmonary fibrosis and COVID-19
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Aug 26, 2020Japanese authorities have chosen Lumipulse® for nasopharyngeal or saliva-based SARS-CoV-2 antigen testing of passengers at their main international airports
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...